Alofisel withdrawn from the EU market

View source ↗

Summary

The EMA has withdrawn Alofisel from the EU market. It determined that the medicine's benefit in Crohn's disease is no longer demonstrated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Alofisel (darvadstrocel)

Snippet

Benefit of medicine used in Crohn’s disease no longer demonstrated